Streetbeat News

Analyst Ratings

SMMT

Summit Therapeutics shares declined following a downgrade by Citigroup from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:31 pm

SMMT

Summit Therapeutics shares fell after Citigroup downgraded the stock from Buy to Neutral, despite raising the price target from $19 to $23.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:28 pm

COST

Goldman Sachs analyst Kate McShane maintains a Buy rating on Costco Wholesale and raises the price target from $876 to $995.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:27 pm

BP

Wells Fargo analyst Roger Read has maintained an Equal-Weight rating on BP but has lowered the price target from $39 to $35.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:26 pm

COST

Wells Fargo analyst George Kelly maintains an Equal-Weight rating on Costco Wholesale and raises the price target from $800 to $850.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:23 pm

LXRX

HC Wainwright & Co. has reiterated its Buy rating for Lexicon Pharmaceuticals, maintaining a price target of $10. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:22 pm

MCD

High-rolling investors are showing a bullish sentiment on McDonald's (NYSE:MCD) through options trading, with a significant number of call options being placed. This activity suggests potential insider information and could indicate a positive outlook for McDonald's stock. Analysts have mixed ratings, with some maintaining neutral or hold positions, while others are more optimistic.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 3:17 pm

AGIO

Agios Pharmaceuticals' stock is experiencing a decline following a downgrade by Leerink Partners from Outperform to Market Perform, along with a reduced price target from $60 to $56.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:16 pm

LEVI

TD Cowen analyst Oliver Chen maintains a Buy rating on Levi Strauss but lowers the price target from $26 to $25.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:15 pm

EXPE

BTIG analyst Jake Fuller maintains a Buy rating on Expedia Group and raises the price target from $150 to $175.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:10 pm